Boulder, Colorado - August 28, 2012 - Bolder BioTechnology, Inc. announced today publication of preclinical research demonstrating utility of interleukin-11 (IL-11) and the company's long-acting IL-11 analog to prevent kidney damage from ischemia reperfusion injury in mice. This work may lead to new therapeutic approaches to prevent acute kidney injury and ischemia reperfusion injury to multiple…
Read more
Bolder BioTechnology Announces $1.2 Million in Qualifying Therapeutic Discovery Project Grants
Boulder, Colorado - November 3, 2010 - Bolder BioTechnology, Inc. today announced that it has been awarded a total of $1.2 million in Qualifying Therapeutic Discovery Project Grants. Grants were awarded for qualified investments under the Qualifying Therapeutic Discovery Project Tax Credit Program, which authorized up to $1 billion in tax credits or grants to biopharmaceutical…
Read more
Bolder BioTechnology Announces $600,000 Grant from NIH to Study Long-Acting IL-11 Analog in Treating Acute Radiation Syndrome
Boulder, Colorado - August 18, 2010 - Bolder BioTechnology, Inc. today announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant totaling $600,000 from the National Institute of Allergy and Infectious Diseases (NIAID) of The National Institutes of Health (NIH). The grant will be used to demonstrate the feasibility of using…
Read more
Bolder BioTechnology Receives $1.2 Million NIH Grant to Continue Development of Long-Acting EPO Analog for Chronic Kidney Disease
Boulder, Colorado - September 17, 2009 - Bolder BioTechnology, Inc. announced today that it has been awarded a $1.2 million Phase II Small Business Innovation Research (SBIR) grant, entitled “Long-Acting EPO Analog for Treating Anemia Associated with Chronic Kidney Disease”, from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of The National Institutes…
Read more